SSA
ALNY icon

Schonfeld Strategic Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-30,000
Closed -$7.29M – 2011
2024
Q2 		$7.29M Sell
30,000
-24,000
-44% -$3.79M 0.05% 446
2024
Q1 		$8.07M Buy
+54,000
New +$9.01M 0.05% 459

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schonfeld Strategic Advisors's ALNY Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 60% in Q1 2026, buying an estimated $9.14M and bringing the position to 71,767 shares worth $23.7M. The position accounts for 0.17% of the portfolio, ranked #120.

Schonfeld Strategic Advisors first reported a position in ALNY in Q3 2016 and has held it in 25 quarters since. The position peaked at $35.2M in Q1 2024. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Schonfeld Strategic Advisors held 71,767 shares of Alnylam Pharmaceuticals worth $23.7M as of Q1 2026.
  • Schonfeld Strategic Advisors bought 26,873 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $9.14M.
  • Alnylam Pharmaceuticals made up 0.17% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #120 holding.
  • Schonfeld Strategic Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2016 and has held it in 25 quarters since.
  • Schonfeld Strategic Advisors's Alnylam Pharmaceuticals position peaked at $35.2M in Q1 2024.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.